Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Diagnostics Commercial

Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19

  • Interviews

Executive Summary

Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.

You may also be interested in...



23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC

23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement

The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

Table

View full table

Topics

Related Companies

Tags:
Coronavirus COVID-19 Diagnostics Commercial
Latest Headlines

Medtech Connect Episode 10: Breaking Down The Transitional Coverage Of Emerging Technologies

Medtronic Hires New Neuromodulation Leader

New ePortal To Simplify Processing & Tracking Of WHO Prequalification Applications

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

See All
UsernamePublicRestriction

Register

MT143597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By